Efficacy of Thymosin alpha1 for Severe Sepsis (ETASS)

Sun Yat-sen University

Status

Completed

Conditions

Severe Sepsis

Treatments

Drug: Thymosin alpha 1

Study type

Interventional

Funder types

Other

Identifiers

NCT00711620

2007015

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.

Full description

Severe sepsis is a disease of infectious origin with a high risk of death. Over the past decade, thymosin alpha1 have already provided clinicians with additional weapon in the fight against infectious diseases, but it is unknown whether thymosin alpha1 is effective in treating severe sepsis.

Enrollment

366 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Severe sepsis according to ACCP/CCM criteria
Patient or legally authorized representative able to provide informed consent

Exclusion criteria

Subject is less than 18 years or more than 85 years of age
If female, the subject is pregnant or nursing
Subject is receiving immunosuppressive therapy such as cyclosporine, azothioprine,or cancer-related chemotherapy
Patient not expected to survive 28 days because of uncorrectable medical condition, such as poorly controlled neoplasm or other end-stage disease
History of bone marrow, lung, liver, pancreas, or small-bowel transplantation
Acute pancreatitis with no established source of infection